HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination.

Objective: To investigate whether persons with treatment-resistant Lyme arthritis-associated HLA alleles might develop arthritis as a result of an autoimmune reaction triggered by Borrelia burgdorferi outer surface protein A (OspA), the Lyme disease vaccine antigen.

Methods: Persons in whom inflammatory arthritis had developed after Lyme disease vaccine (cases) were compared with 3 control groups: 1) inflammatory arthritis but not Lyme disease vaccine (arthritis controls), 2) Lyme disease vaccine but not inflammatory arthritis (vaccine controls), and 3) neither Lyme disease vaccine nor inflammatory arthritis (normal controls). HLA-DRB1 allele typing, Western blotting for Lyme antigen, and T cell reactivity testing were performed.

A comparison of two treatment regimens of ceftriaxone in late Lyme disease.

Background: The optimal duration of treatment for patients with late Lyme disease is unresolved.

Methods: In a prospective, open label, randomized, multi-center study, a 14 day course of ceftriaxone was compared to 28 days of therapy. Entry criteria included objective abnormalities compatible with late Lyme disease and serologic reactivity to Borrelia burgdorferi.

The relationship of HLA antigens to doxycycline induced apoptosis in immortalized B cells.

Previous studies have shown two subsets of Lyme disease (LD) patients: a seropositive group with a high frequency of the HLA class II antigen, HLA-DR7 (DR7+), and a seronegative group with a low frequency of HLA-DR7 (DR7-). The present study examined the hypothesis that the absence or presence of this antigen may play a role in the mode of B cell death induced by doxycycline. B cells, obtained from one HLA-DR7- (AL7N) and one HLA-DR7+ (MM7P) normal volunteers, were immortalized using Epstein-Barr Virus (EBV).

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with fluconazole plus amphotericin B (AmB) deoxycholate (0.7 mg/kg per day, with the placebo/AmB component given only for the first 5-6 days) as therapy for candidemia due to species other than Candida krusei in adults without neutropenia. A total of 219 patients met criteria for a modified intent-to-treat analysis.